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A B S T R A C T   
These guidelines are intended to provide an in-depth review of current knowledge and assist the planning and 
implementation of studies for evaluating the efficacy of parasiticides in reducing transmission of vector-borne 
pathogens (VBPs) to dogs and cats. At present, the prevention of VBP transmission in companion animals is 
generally achieved through the administration of products that can repel or rapidly kill arthropods, thus pre-
venting or interrupting feeding before transmission occurs. The present guidelines complement existing guide-
lines, which focus on efficacy assessment of parasiticides for the treatment, prevention and control of flea and 
tick infestations, but also give guidance for studies focused on other vectors (i.e. mosquitoes and phlebotomine 
sand flies). The efficacy of parasiticides in reducing VBP transmission can be evaluated through laboratory or 
field studies. As such, the present guidelines provide recommendations for these studies, representing a tool for 
researchers, pharmaceutical companies and authorities involved in the research, development and registration of 
products with claims for reducing VBP transmission in dogs and cats, respecting the overall principles of the 3Rs 
(replacement, reduction and refinement). Gaps in our current understanding of VBP transmission times are 
herein highlighted and the need for further basic research on related topics is briefly discussed.   
1. Introduction 
Ticks, fleas, phlebotomine sand flies, mosquitoes, lice and, to a lesser 
extent, other arthropods (e.g., black flies, biting midges, triatomine bugs 
and keds) may cause direct damage (e.g., skin injuries, blood loss and 
allergic reactions) to their hosts, and can also inoculate neurotoxins and 
transmit a range of pathogens, including bacteria, protozoa, viruses and 
helminths. Vector-borne diseases (VBDs) threaten the health and 
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welfare of dogs and cats globally (Beugnet, 2013), with many 
vector-borne pathogens (VBPs), including Bartonella spp., Dirofilaria 
spp., Leishmania spp. and Rickettsia spp., being of zoonotic concern 
(Colwell et al., 2011; Dantas-Torres et al., 2012; Kilpatrick and Ran-
dolph, 2012; Otranto et al., 2013). 
The existing World Association for the Advancement of Veterinary 
Parasitology (W.A.A.V.P.) guidelines for evaluating the efficacy of par-
asiticides for the treatment, prevention and control of flea and tick in-
festations on dogs and cats (Marchiondo et al., 2013) are not focused on 
VBP transmission, prevention or treatment. Consequently, the present 
W.A.A.V.P. guidelines are intended to provide researchers, pharma-
ceutical companies and authorities with recommendations for studies 
evaluating the efficacy of parasiticides in reducing the risk of VBP 
transmission in dogs and cats. Moreover, the existing guidelines do not 
include some insects of veterinary significance (e.g., mosquitoes and 
phlebotomine sand flies), which are vectors of pathogens to dogs and 
cats. In principle, the transmission of pathogens can be reduced either by 
repelling (i.e. repellent effect), disrupting feeding or by rapidly killing 
arthropod vectors (i.e. killing effect) before pathogen transmission oc-
curs. There is a need to harmonize studies evaluating efficacy of para-
siticides in reducing the risk of VBP transmission to dogs and cats, as 
indicated by the recently drafted European Medicines Agency (EMA) 
guidelines for veterinary medicinal products for the prevention of 
transmission of VBDs in dogs and cats (EMA, 2018). 
Traditionally, W.A.A.V.P. guidelines have targeted eukaryotic path-
ogenic organisms falling within the classical definition of ‘parasite’. In 
addition to ‘classical’ vector-borne parasites (e.g., Dirofilaria spp., 
Leishmania spp. and Babesia spp.), the present guidelines also encompass 
vector-borne bacteria (e.g., Anaplasma spp., Borrelia spp., Ehrlichia spp. 
and Rickettsia spp.), which may be transmitted to dogs and cats by ticks 
or fleas (Table 1). Conversely, vector-borne viruses (e.g., tick-borne 
encephalitis virus) are not considered within these guidelines due to 
the limited hazard they pose, at present, to the health of dogs and cats 
(Reperant et al., 2016). In this context, the present guidelines provide 
recommendations for studies evaluating the efficacy of parasiticides in 
reducing VBP transmission in dogs and cats. They will represent a tool 
for researchers, pharmaceutical companies and authorities involved in 
the research, development and registration of products with claims for 
reducing VBP transmission in dogs and cats and concurrently respecting 
the overall principles of the 3Rs (replacement, reduction and 
refinement). 
2. Aspects that may affect VBP transmission 
While scientific knowledge on the biology of VBPs and their vectors 
has increased in recent decades (Schorderet-Weber et al., 2017; Otranto, 
2018), there is still a need to translate much of this knowledge into 
effective prevention tools and strategies for preventing VBP trans-
mission. Indeed, several aspects of the vector-pathogen-host interaction 
do influence the efficacy of parasiticides in reducing VBP transmission in 
dogs and cats. Therefore, relevant aspects, like route of transmission, 
feeding behaviour and duration of the vector’s feeding and pathogen 
transmission rates and times, migration paths and incubation time of 
pathogens in their vectors, must be considered when designing efficacy 
studies. 
Regarding routes of transmission, some pathogens are inoculated (e. 
g., Babesia spp., Leishmania spp. and Rickettsia spp.) during blood feeding 
(Schorderet-Weber et al., 2017), whereas others (e.g., Dirofilaria immitis) 
are deposited onto the skin and penetrate actively through the bite 
wound (Venco et al., 2011). In contrast, other pathogens are transmitted 
through ingestion of vectors (e.g., Hepatozoon canis and Dipylidium 
caninum) or paratenic hosts (e.g., Hepatozoon americanum) (Baneth, 
2011). Additionally, the transmission by dog bites (e.g., Babesia gibsoni), 
vertical (e.g., H. canis and Leishmania infantum), venereal (e.g. 
L. infantum) and blood transfusion transmission (e.g., Anaplasma phag-
ocytophilum, Anaplasma platys, Babesia spp., Ehrlichia canis and 
L. infantum) have also been demonstrated for a range of VBPs of dogs and 
cats. 
Feeding behaviour of vectors and pathogen transmission times are 
governed by a number of variables related to the vectors, the pathogens 
and the susceptible vertebrate hosts (de la Fuente et al., 2017; Otranto, 
2018). Overall, the duration of the blood-feeding period is shorter in 
insects (e.g., sand flies, mosquitoes and black flies) as compared to 
ixodid ticks (Petrić et al., 2012; Bates, 2017). Arthropod vectors may be 
attracted by different host stimuli and use different strategies to locate 
and approach the host. Accordingly, some may land (e.g., flying insects), 
while others crawl (e.g., ticks) or jump (e.g., fleas) on the host. For 
instance, mosquitoes and other flying insects (e.g., sand flies) are highly 
mobile and, once landed on the host, they feed rapidly, thus having a 
short-lasting contact with their hosts (Gingrich and Williams, 2005; 
Faraji et al., 2014). With regard to fleas, many cat fleas (Ctenocephalides 
felis) will begin feeding within minutes of arriving on their host, with the 
majority of them completing the blood meal within 1 h (h) of arrival 
(Cadiergues et al., 2000). Hard ticks (Ixodidae), however, are slow 
feeders and may feed for several hours or days, thus having a relatively 
long-lasting contact with their hosts (Sonenshine and Roe, 1993; Dan-
tas-Torres et al., 2012). Consequently, transmission times of bacterial 
and parasitic pathogens are usually shorter with insect vectors (from 
seconds to minutes) as compared to ticks (from a few hours to several 
days). 
Pathogen transmission is influenced by several factors, including 
pathogen pre-activation times (Kidd and Breitschwerdt, 2003; Otranto, 
2018). In fact, some tick-borne pathogens require a pre activation 
period, resulting in a longer transmission time. An example is repre-
sented by Borrelia burgdorferi spirochetes causing Lyme disease, which 
are usually transmitted by infected ixodid ticks within 24–48 h following 
their attachment to the host (Hajdušek et al., 2013). Although the de-
terminants affecting pathogen pre-activation times are not completely 
understood, the ingestion of blood is reputed to play a role in this pro-
cess (Socolovschi et al., 2009). For instance, interrupted feeding may 
reduce the transmission time of Rickettsia rickettsii by Amblyomma aur-
eolatum from more than 10 h to 10 min (min) (Saraiva et al., 2014) and 
Babesia canis by male Dermacentor reticulatus from 48 h to 8 h (Varloud 
et al., 2018). In addition to the speed of transmission of VBPs by ticks, 
establishment of infections may be dependent on a minimum inocula-
tion dose for bacterial pathogens like A. phagocytophilum (Fourie et al., 
2019). While the transmission times and their influencing factors may be 
considered in the design of laboratory studies, they cannot be easily 
assessed and controlled under field conditions. In any case, all factors 
potentially affecting VBP transmission should be considered when 
designing efficacy studies. 
3. Parasiticides and their role in preventing VBP transmission 
Theoretically, the transmission of VBPs can be prevented either by 
completely impeding feeding by arthropods or by ensuring that 
arthropod vectors are killed before pathogens are transmitted to the 
hosts. The efficacy of a parasiticide against a given arthropod vector 
does not imply a significant reduction of the risk of VBP transmission per 
se and therefore specific studies are required by authorities in order to 
pursue label claims in this respect. As a result of the lack of specific 
guidelines, until now the approval of a parasiticide as efficacious in 
reducing the risk of VBP transmission has been handled on a case-by- 
case basis by regulatory authorities and respective registrant com-
panies (Bobey, 2015). 
A number of pyrethroids (e.g., permethrin, deltamethrin and flu-
methrin) with repellent and anti-feeding effects have been proven effi-
cacious to reduce the risk of transmission of VBPs (e.g., B. canis, E. canis 
and L. infantum) in both laboratory and field studies (Jongejan et al., 
2011, 2015, 2016; Fourie et al., 2013b, c; Brianti et al., 2014). Other 
chemical compounds, by virtue of their fast killing effect, may also 
reduce the risk of VBP transmission in dogs and cats. For example, 
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Table 1 
Pathogens causing vector-borne diseases in dogs and cats, the disease they cause, their arthropod vectors, transmission times. The desired features of a product to 
prevent pathogen transmission to dogs and cats are described, but do not replace the need for specific VBP prevention studies. N/A indicates that no literature is 
available.  
Pathogen Disease Vector Minimum reported 
transmission time a 
Theoretical desired effect of a 








Non-pathogenic Fleas (Ctenocephalides felis) 
and lice (Heterodoxus 
spiniger) 
Immediate Repellent or fast killing effect (all fleas 
and lice killed as soon as possible after 






Ticks (Ixodes spp.) Within hours 
(establishment after 48 h, 
to dogs) 
Repellent or fast killing effect (all ticks 
killed in <48 h) 
Fourie et al. (2019) 
Anaplasma platys Canine cyclic 
thrombocytopenia 
Unknown (ticks are 
suspected vectors) 
Unknown Unknown N/A 
Babesia canis Canine babesiosis Ticks (Dermacentor 
reticulatus) 
36 h (8 h in interrupted 
feeding experiment) (to 
dogs) 
Repellent or fast killing effect (all ticks 
killed in <36 h) 
Varloud et al. 
(2018) 
Babesia conradae Canine babesiosis Unknown (ticks are 
suspected vectors) 
Unknown Repellent or fast killing effect (all ticks 
killed in <36 h); based on minimal 
transmission time for B. canis 
N/A 
Babesia felis Feline babesiosis Unknown (ticks are 
suspected vectors) 
Unknown Repellent or fast killing effect (all ticks 
killed in <36 h); based on minimal 
transmission time for B. canis 
N/A 
Babesia gibsoni Canine babesiosis Ticks (Haemaphysalis 
longicornis) 
Unknown Repellent or fast killing effect (all ticks 
killed in <36 h); based on minimal 
transmission time for B. canis 
N/A 
Babesia rossi Canine babesiosis Ticks (Haemaphysalis 
elliptica) 
Unknown Repellent or fast killing effect (all ticks 
killed in <36 h); based on minimal 
transmission time for B. canis 
N/A 
Babesia vogeli Canine babesiosis Ticks (Rhipicephalus 
sanguineus sensu lato) 
Unknown Repellent or fast killing effect (all ticks 
killed in <36 h); based on minimal 
transmission time for B. canis 
N/A 
Babesia vulpes Canine babesiosis Unknown (ticks are 
suspected vectors) 
Unknown Repellent or fast killing effect (all ticks 
killed in <36 h); based on minimal 
transmission time for B. canis 
N/A 
Bartonella henselae Feline bartonellosis Fleas (C. felis) Immediate via contact 
with flea faeces (but after 
fleas feed and digest the 
blood) 
Repellent or fast killing effect (all fleas 
killed as soon as possible after coming in 
contact with the host) 
Bouhsira et al. 
(2013a) 
Borrelia burgdorferi Canine Lyme disease Ticks (Ixodes spp.) 24 h (to hamsters) Repellent or fast killing effect (all ticks 
killed in <24 h) 
Piesman et al. 
(1987) 
Cytauxozoon felis Feline cytauxzoonosis Ticks (Amblyomma 
americanum) 
48 h (to cats) Repellent or fast killing effect (all ticks 
killed in <48 h) 
Thomas et al. 
(2018) 
Dipylidium caninum Canine dipylidiosis Fleas (C. ides felis, 
Ctenocephalides canis) and 
lice (Trichodectes canis, 
Felicola subrostratus) 
Immediate after the 
ingestion (via ingestion of 
the arthropod vector) 
Repellent or fast killing effect (all fleas 
and lice killed as soon as possible after 
coming in contact with the host); 
parasiticides with additional larvicial 
and ovicidal effiacy are more effective 
in reducing the overall risk transmission 
N/A 
Dirofilaria immitis Canine and feline 
heartworm disease 
Mosquitoes (several genera 
and species) 
Immediate Repellent (all mosquitoes killed as soon 
as possible after coming in contact with 
the host) 
N/A 
Dirofilaria repens Canine and feline 
subcutaneous dirofilariosis 
Mosquitoes (several genera 
and species) 
Immediate Repellent (all female mosquitoes killed 
as soon as possible after coming in 
contact with the host) 
N/A 
Ehrlichia canis Canine monocytic 
ehrlichiosis 
Ticks (Rh. sanguineus s.l.) within hours (3 h) (to 
dogs) 
Repellent or fast killing effect (all ticks 
killed in <3 h) 
Fourie et al. 
(2013a) 
Hepatozoon canis Canine hepatozoonosis Ticks (Rh. sanguineus s.l., 
Rhipicephalus turanicus, 
Amblyomma ovale) 
Immediate (via ingestion 
of infected ticks) 
Repellent or fast killing effect (all ticks 
killed as soon as possible after coming in 
contact with the host) which result in 
the reduction of tick population 
N/A 
Leishmania infantum Canine and feline 
leishmaniosis 
Sand flies (several genera 
and species) 
Immediate Repellent or fast killing effect (all 
female sand flies killed as soon as 
possible after coming in contact with the 
host)  
Rangelia vitalii Canine rangeliosis Ticks (Amblyomma 
aureolatum) 
Unknown Repellent or fast killing effect (all ticks 
killed in <36 h); based on minimal 
transmission time for B. canis 
Soares et al (2018) 
Rickettsia conorii Canine spotted fever 
rickettsiosis or canine 
Mediterranean spotted 
fever 
Ticks (Rh. sanguineus s.l., 
Rh. turanicus) 
Unknown Repellent or fast killing effect (all ticks 
killed in <10 h); based on minimal 
transmission time for R. rickettsii 
N/A 
Rickettsia felis Feline flea-borne 
rickettsiosis 
Fleas (C. felis) Immediate Repellent or fast killing effect (all fleas 
killed as soon as possible after coming in 
contact with the host) 
Wedincamp and 
Foil (2002) 
(continued on next page) 
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isoxazolines (e.g., afoxolaner, fluralaner, lotilaner and sarolaner) might 
be indicated for the prevention of the transmission of several tick-borne 
(e.g., A. phagocytophilum, B. canis and Bo. burgdorferi) and flea-borne 
pathogens (e.g., Acanthocheilonema reconditum and D. caninum) (Beug-
net et al., 2014; Taenzler et al., 2015; Baker et al., 2016; Honsberger 
et al., 2016; Geurden et al., 2017; Gopinath et al., 2018). 
Insecticides and acaricides are available as topical (i.e. spot-on, spray 
or collar) or oral (i.e. chewables or hard tablets) formulations. These 
products may act by killing (i.e. insecticidal and acaricidal products, 
formulated for topical or oral applications) or repelling (i.e. repellent 
products, formulated for topical application only) arthropods. There-
fore, these products can prevent arthropod feeding or interrupt the 
feeding process in its early phases, ultimately reducing the risk of VBP 
transmission to dogs and cats (Otranto and Wall, 2008) and potentially 
reducing the ingestion of vectors while these animals are scavenging and 
grooming (Baneth, 2011). Some active ingredients like pyrethroids have 
the unique feature of possessing dual killing (insecticidal, acaricidal, or 
both) and repelling effects, whose efficacy may vary depending on the 
active ingredient, formulation and target arthropod (Beugnet and Franc, 
2012). On the other hand, the combination of several active ingredients 
with different modes of action within the same formulation enables 
certain products to attain a broad spectrum of activity targeting several 
arthropods (e.g., fleas, ticks, mites, lice, mosquitoes and sand flies). 
Once administered to the host, parasiticides can act before the target 
arthropods start feeding, as soon as they begin to feed or following a 
certain lag time from the initiation of feeding. This depends mainly on 
the intrinsic properties and mode of action (i.e. acting via contact, 
ingestion, or both) of each parasiticide, and is independent (or less 
dependent) on the route of administration (i.e. topical versus oral). For 
instance, some products display a pronounced volatility (e.g., dieth-
yltoluamide - DEET, which is not available for use in dogs and cats), 
enabling the repellency of certain arthropod vectors prior to (e.g., 
mosquitoes and sand flies) or soon after (e.g., ticks and fleas) their 
contact with the host (Bissinger and Roe, 2010). Other products display 
a lower volatility (e.g., pyrethroids, which are available for use in dogs 
and cats) and require the contact between the arthropods and the host, 
only after which arthropods are repelled (Bissinger and Roe, 2010). The 
killing effect can be achieved either through external contact (i.e. the 
arthropod dies after coming into contact with the parasiticide on the fur 
or the skin of the treated host) or ingestion (i.e. the arthropod dies after 
ingesting the parasiticide, with the blood of the treated host). Therefore, 
depending on the active ingredient(s) present in the formulation, a 
product may prevent attachment (i.e. repellent effect), disrupt an 
already existing contact between the arthropod and the host (also 
referred to as expellent effect), cause the close to or immediate death of 
the arthropod (killing effect), or interfere with egg fertility and subse-
quent development of the arthropod (i.e. growth inhibition) (Halos 
et al., 2012). 
The mode of action of different active compounds should be evalu-
ated regarding their impact on the biology, ecology and parasitic 
behaviour of each arthropod and VBP. Parasiticides licensed for pre-
venting or treating ectoparasite infestations on dogs and cats belong to 
several chemical families, namely formamidines (e.g., amitraz), neon-
icotinoids (e.g., dinotefuran and imidacloprid), phenylpyrazoles (e.g., 
fipronil), indoxacarb (oxadiazine), macrocyclic lactones (MLs) of the 
spinosyn group (e.g., spinosad) and MLs of the avermectin/milbemycin 
group (e.g., selamectin), and synthetic pyrethroids (e.g., deltamethrin, 
flumethrin and permethrin) (Beugnet and Franc, 2012). Recently, iso-
xazoline class molecules have been successfully introduced as parasiti-
cides for dogs and cats (Pfister and Armstrong, 2016; Weber and Selzer, 
2016; Wright, 2018). When administered to dogs, these molecules 
display a fairly rapid onset of action against existing infestations (i.e. 
curative effect), starting from 4 h and reaching >90 % of killing effect in 
about 12 h, with the highest efficacy in killing ticks displayed within 24 
h (Beugnet et al., 2014; Pfister and Armstrong, 2016; Geurden et al., 
2017; Murphy et al., 2017). Fluralaner and afoxolaner were found also 
to kill up to 100 % of Aedes (e.g., Aedes aegypti), Anopheles (e.g., 
Anopheles gambiae) and Culex (e.g., Culex pipiens) mosquitoes, and Lut-
zomyia (e.g., Lutzomyia longipalpis) and Phlebotomus (e.g., Phlebotomus 
argentipes) sand flies, 24 h after artificial feeding on blood containing 
different concentrations of these compounds (Miglianico et al., 2018). 
Isoxazolines in oral formulations were successfully used in dogs for 
the prevention of the transmission of B. canis by D. reticulatus (afox-
olaner, Beugnet et al., 2014; fluralaner, Taenzler et al., 2015; lotilaner, 
Cavalleri et al., 2017; sarolaner, Geurden et al., 2017) as well as of Bo. 
burgdorferi and A. phagocytophilum by Ixodes scapularis (sarolaner, 
Honsberger et al., 2016). Considering the toxicity of most synthetic 
pyrethroids to cats, the efficacy of an isoxazoline (e.g., sarolaner in as-
sociation with selamectin) has been recently proposed for preventing 
feline VBDs (Otranto and Little, 2017). A fast-killing spot-on combina-
tion of fipronil, amitraz and (S)-methoprene was demonstrated to inhibit 
the transmission of B. canis by De. reticulatus (Jongejan et al., 2011) and 
of Bo. burgdorferi and A. phagocytophilum by I. scapularis (McCall et al., 
2011); however, this combination is no longer commercialized. The 
efficacy of any product in blocking VBP transmission is however also 
dependent on the pathogens’ transmission times; quickly transmitted 
pathogens such as E. canis (transmitted by Rh. sanguineus sensu lato (s.l.) 
in about 3 h, in in vitro conditions) (Fourie et al., 2013a) are better 
targeted by synthetic pyrethroids than isoxazolines (Jongejan et al., 
2016). In fact, pyrethroids have been proven efficacious in preventing 
the transmission of rapidly transmitted VBPs, such as E. canis (Jongejan 
et al., 2011; Fourie et al., 2013a, c; Stanneck and Fourie, 2013) and 
L. infantum (Brianti et al., 2014), as well as slower transmitted VBPs such 
as Bo. burgdorferi, A. phagocytophilum (Blagburn et al., 2004) and B. canis 
Table 1 (continued ) 
Pathogen Disease Vector Minimum reported 
transmission time a 
Theoretical desired effect of a 






Rickettsia rickettsii Canine spotted fever 
rickettsiosis or canine 
Rocky Mountain spotted 
fever 
Ticks (several genera and 
species) 
10 h (10 min in an 
interrupted feeding 
experiment with Am. 
aureolatum) (to dogs) 
Repellent or fast killing effect (all ticks 
killed in <10 h) 
Saraiva et al. 
(2014)  
a The transmission time is defined here as the minimum period required from blood feeding initiation by the arthropod vectors to actual pathogen transmission to the 
vertebrate host. In all studies with ticks, transmission times are shortened if ticks are initially placed on a host to start feeding and then removed from this host and 
placed on a second host (=interrupted feeding experiments). Moreover, the transmission efficiency by ticks increases with time (the longer the feeding period, the 
higher is the proportion of animals infected) as well as the establishment of infections in dogs, being dependent on the minimum inoculation dose. Unless otherwise 
stated, pathogen transmission occurs by bite. Within this column, ‘immediate’ means within few minutes. 
b Based on data currently available from studies conducted with dogs or cats. In some cases, transmission times using other animal models may be shorter than those 
using dogs or cats (e.g., A. phagocytophilum needs 48 h to establish infection in dogs, but only 24 h in mice). When the specific transmission time is unknown, theoretical 
desired effects of parasiticides are inferred from data obtained with phylogenetically close organisms (e.g., desired effects of parasiticides against Babesia spp. 
transmission are inferred from data obtained with B. canis). 
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(Jongejan et al., 2011; Fourie et al., 2013b; Navarro et al., 2015), under 
laboratory or field conditions. 
The efficacy requirements for a parasiticide to be registered may vary 
according to national and regional regulatory authorities. For instance, 
to be licensed in Europe, a parasiticide should have efficacies of >95 % 
within 24 h and >90 % within 48 h post-treatment against existing flea 
and tick infestations, respectively (i.e. curative or immediate efficacy). 
Likewise, a parasiticide should have efficacies of >95 % within 24 h and 
>90 % within 48 h post subsequent infestations by fleas and ticks, 
respectively, to assess the persistent efficacy (Marchiondo et al., 2013; 
EMA, 2016a; Pfister and Armstrong, 2016). In the USA, the product 
should have an efficacy of >90 % against both fleas and ticks (Pfister and 
Armstrong, 2016). However, thus far neither the evaluation time points 
nor the required efficacy thresholds for such time points have been 
validated for their relevance in the reduction of the VBP transmission 
risk. In any case, studies on the speed of kill (SOK) and persistent effi-
cacy may indicate the potential of reducing the risk of VBP transmission. 
Accordingly, products with a rapid onset of action and sustained SOK 
throughout the treatment duration have the potential to reduce this risk 
(Dantas-Torres and Otranto, 2016; Schorderet-Weber et al., 2017), as 
demonstrated by a number of studies in dogs and cats (Stanneck et al., 
2012; Tielemans et al., 2014; Fourie et al., 2015; Geurden et al., 2017). 
While laboratory studies are important for assessing the efficacy of a 
product in reducing the risk of VBP transmission, a spectrum of potential 
confounding factors (e.g., interrupted feeding and co-infection with 
multiple pathogens) can occur under field conditions. As such, field 
studies are beneficial to confirm the data obtained in the laboratory. 
Even if study data generally confirm the efficacy of repellents and fast- 
killing parasiticides in reducing the risk of VBP transmission, none of the 
available products can ever ensure a total protection. Therefore, inte-
grated control strategies are advocated by the scientific community for 
VBP prevention (e.g., association of ectoparasiticides and MLs for the 
prevention of heartworm disease in dogs and cats). 
4. Evaluation of efficacy in reducing VBP transmission 
The label claim ‘reduction of the risk of infection with < name of VBP 
> via transmission by < name of the vector> ‘needs to be requested from 
the regulatory authority [e.g., the Food and Drug Administration (FDA) 
in the USA, the European Medicines Agency in the European Union 
(EMA) and the Ministry of Agriculture, Livestock, and Food Supply 
(MAPA) in Brazil], as an extension of an existing label claim, and should 
be based on laboratory and/or field studies. While experimental studies 
are considered mandatory by the FDA and EMA, field studies are 
generally acknowledged as ‘supportive’. However, regulatory agencies 
may issue a preventive indication based on well-designed field studies, 
which are conducted according to the Good Clinical Practice (GCP) 
guidelines (VICH, 2000). 
For all studies involving the use of animals, utmost care must be 
given to the welfare of any animals used and all procedures must be 
approved by regulatory authorities and an animal ethics committee 
(EMA, 2016b). The life cycle and pathogenicity of the VBP of interest 
should be also considered to avoid unnecessary suffering of infected 
animals, which should be treated or humanely euthanized after use, 
based on the recommendation of the study director/investigator and 
approval of an animal ethics committee. 
The principle of the 3Rs (replacement, reduction and refinement) 
should be taken into account when clinical studies are designed and 
conducted. The use of animal-free in vitro methods can help to better 
understand some phenomena such as vector-VBP relationships or 
feeding behaviour of vectors prior to the use of animals, thus enabling 
the comprehensive set-up of meaningful animal studies. Suitable study 
conditions (e.g., care of animal and study procedures) should be used to 
avoid pain, suffering or distress of the animals as much as possible and to 
minimize the number of animals used (EMA, 2016b). 
4.1. In vitro studies: artificial feeding systems 
Artificial feeding systems have been increasingly used to infect ar-
thropods with pathogens, assess transmission times of pathogens (Fourie 
et al., 2013a, 2019) and to test the efficacy of systemic parasiticides 
(Kroeber and Guerin, 2007) as well as the efficacy of parasiticides in 
preventing VBP transmission. However, such in vitro efficacy data are 
usually regarded only as ‘supportive’ by authorities. Different artificial 
feeding systems have been implemented for fleas (C. felis) (Bouhsira 
et al., 2013a, b), mosquitoes (Luo, 2014), sand flies (Ghosh, 1994) and 
some tick species (e.g., Rh. sanguineus s.l.) (Fourie et al., 2013a). To 
assess the efficacy and SOK, parasiticides are solubilized in a blood 
medium and fed to the arthropods through a silicone membrane (i.e. 
Parafilm® or Nescofilm) or skin derived from 1 to 5 day-old chicks 
(Ghosh, 1994; Bouhsira et al., 2013a, b; Luo, 2014). Exposure time will 
vary according to arthropod vectors. 
The successful implementation of these systems is assessed based on 
the feeding rates of arthropods, which in the case of ticks, is also 
conditioned by the size of these parasites’ mouthparts (e.g., artificial 
feeders have thus far yielded higher feeding rates in Ixodes spp. than in 
Rhipicephalus spp.) (Fourie et al., 2013a, 2019). One limitation of arti-
ficial feeders is the lack of innate and adaptive immune responses from 
the host, which may play a role in arthropod feeding and VBP trans-
mission (Cantillo et al., 2014; Kamhawi et al., 2014; Shaw et al., 2016; 
de la Fuente et al., 2017). Therefore, results obtained from studies using 
artificial feeders should be interpreted cautiously. Indeed, a recent study 
showed that while the presence of A. phagocytophilum deoxyribonucleic 
acid (DNA) could be detected in blood samples taken from artificial 
feeders on which infected Ixodes ricinus ticks had fed for only 6 h, the 
establishment of infection in dogs required 48 h to occur under exper-
imental conditions (Fourie et al., 2019); hence, the transmission to dogs 
was assumed to be dependent on a minimum inoculation dose (Fourie 
et al., 2019). 
Artificial feeding systems are of limited use for testing compounds 
acting only by contact following topical administration on dogs and cats. 
Moreover, further research is needed to validate the use of these systems 
in studies evaluating the efficacy of parasiticides in the prevention of 
VBP transmission. 
4.2. In vivo studies 
In vivo studies to demonstrate efficacy of parasiticides in reducing 
VBP transmission in dogs and cats can be conducted under both labo-
ratory and/or field conditions. In both cases, studies should follow GCP 
guidelines (VICH, 2000) if the results are intended to be submitted to a 
regulatory authority. The study design must be adequate for the inten-
ded purpose and may be different from studies solely evaluating the 
efficacy of parasiticides for the treatment, prevention and control of flea 
and tick infestations on dogs and cats (Marchiondo et al., 2013). 
Laboratory studies should include an untreated control group and be 
designed to test final formulations as close to the minimum recom-
mended dose as possible using the approved commercial product, if 
available. Field studies usually involve privately owned pets, which 
makes the use of a negative control group less feasible, except if the 
disease is not highly pathogenic and is relatively easy to treat. While in 
other geographic regions field studies still frequently include a negative 
control (Coura-Vital et al., 2018), there is currently a growing concern in 
using untreated control groups in studies conducted in the EU. When the 
inclusion of a negative control group is not feasible, the investigational 
product should be compared to an established treatment (i.e. 
non-inferiority clinical studies), available for the targeted label claim. 
Products should be used at the registered/intended dose and adminis-
tered according to label recommendations. 
The set-up of studies to evaluate the prevention of VBP transmission 
differs from the classical designs for the evaluation of efficacy against 
the arthropods themselves. As an example, in laboratory studies 
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evaluating the efficacy against tick-borne pathogen transmission, the 
design might foresee tick counts and removals only several days after the 
artificial infestation (Cavalleri et al., 2017), to ensure sufficient time for 
transmission to occur in the control group. On the other hand, in studies 
evaluating the efficacy of parasiticides for the treatment, prevention and 
control of tick infestations on dogs and cats, the tick count and removal 
is usually done at 48 h, or at earlier time-points (e.g., 6, 12 and 24 h) in 
the case of SOK studies (Marchiondo et al., 2013). 
The duration and frequency of follow-ups of infestations and moni-
toring of animals and the diagnosis of infection depend on the pathogens 
and models under investigation (see section ‘5. Specific study designs’ 
for details). The transmission of pathogens to hosts can be detected by 
several means, varying according to the target pathogen, including 
cytology, serology, molecular biology (e.g., polymerase chain reaction 
(PCR)) and, to a much lesser extent, by culturing (Bouhsira et al., 2013a, 
b; Fourie et al., 2013a, 2019). Usually several diagnostic methods are 
used in combination, including serology (to assess the presence of an-
tibodies against the pathogens or even pathogen antigens), PCR (to 
detect the pathogen’s DNA), cytology, histology and culture (to detect 
the pathogen itself). Animals should be followed-up for a sufficiently 
long period, which usually corresponds to the prepatent period of each 
pathogen, to allow detection of the target pathogen by one or more 
diagnostic tests. Relevant clinical parameters for the respective VBD 
should also be considered to assess the patency of infections and to allow 
for rescue treatments in a timely manner. Study protocols should define 
the identified ‘rescue treatments’ and the specific laboratory or clinical 
criteria that trigger their use (for details, see ‘5. Specific study designs’). 
While the level of exposure to the vectors may be pre-determined in 
laboratory studies, this is unfeasible in field studies, where the number 
of arthropods infesting and/or biting each individual animal as well as 
the pathogen load in the arthropods is unpredictable. As such, gener-
ating baseline prevalence data is imperative to estimate the risk of 
infection with the target pathogen(s) in the study area. 
4.2.1. Laboratory studies 
Laboratory studies require an untreated control group. Whenever 
possible, a pre-inclusion testing of a slightly larger number of animals 
should be done to evaluate their attractiveness to the parasitic arthro-
pods being used. This will allow the randomization of animals by group 
allocation according the respective pre-inclusion counts and exclusion of 
the surplus animals with lowest attractiveness. Each laboratory study 
design may vary according to the vectors under investigation (e.g., 
flying versus non-flying insects), VBPs (e.g., transmission time and 
prepatent period) and investigational product (e.g., mode of action and 
formulation). Moreover, the study design will also depend on the 
intended claim (e.g., repellent versus killing efficacy). 
In laboratory studies, animals should be challenged with infective 
arthropods at least at the beginning and the end of the claim duration. 
For instance, for a 1-month claim, animals need to be challenged within 
the first 2 days post-treatment and not earlier than day 28 post- 
treatment. Arthropods used in experimental studies must be infected 
by the pathogen of interest and, animals should be followed up beyond 
the actual challenge time points for a period that is equal or longer than 
the prepatent period of the infection caused by the pathogen (e.g., at 
least 5 months for Di. immitis), to allow its detection by one or more 
diagnostic tests. Usually, it is advisable to combine different diagnostic 
methods in order to increase the probability of detection of pathogens 
with both short (e.g., Babesia spp. and A. phagocytophilum) and long (e. 
g., Dirofilaria spp. and E. canis) prepatent periods (Otranto et al., 2010a). 
4.2.1.1. Preparation of arthropods to be used in laboratory studies. Lab-
oratory studies evaluating the efficacy of parasiticides for the prevention 
of VBP transmission depend on the successful establishment of labora-
tory colonies of infected arthropod vectors. As an alternative, pop-
ulations of naturally infected arthropods can also be used (e.g., 
I. scapularis naturally infected with Bo. burgdorferi), provided that the 
level of infection in the vector population is sufficiently high to allow 
experimental challenge. Moreover, it is fundamental to properly confirm 
the identity of the target arthropods that will be used in the studies, 
either based on morphology or genetics, which is particularly recom-
mended for some species groups (e.g., Rh. sanguineus s.l.) (Nava et al., 
2018). 
The successful infection of ticks and fleas with a specific VBP de-
pends on their feeding on either an infected animal or an artificial 
feeding system containing infected blood (either blood from a naturally 
infected animal or originally non-infected blood mixed with cultured 
pathogens). The isolates used to experimentally infect the arthropods 
should belong to a known strain, but if not, the isolates should ideally be 
genotyped. If an infected animal is used as a source of infection for the 
arthropods, the animal should be a naïve, purposed-bred dog or cat, 
though other animals may be used as a source of infection, such as 
infected sheep as a source of A. phagocytophilum for I. ricinus (Fourie 
et al., 2019). The presence of co-infections should be excluded. 
Depending on the infectivity, pathogenicity and immunogenicity of the 
VBP of interest, special measures (e.g., administration of corticoids or 
splenectomy) may be required to enhance pathogen multiplication in 
the animal, thus facilitating the infection of the arthropod vector. 
The species and life stage of arthropods to be used should be based on 
vector competence and the biology of the VBP. For example, one should 
consider whether the pathogen is passed transovarially and/or trans-
stadially in the specific vector. Since the successful infection of any 
vector depends on their acquisition of pathogens during feeding on an 
infected host, special attention should be given to the timing of infes-
tation, which should coincide with the expected period of parasitaemia/ 
bacteraemia. This is especially relevant for ticks, which need to feed up 
to repletion on a parasitaemic/bacteraemic animal, which, depending 
on the tick species and developmental stage, may take from a few to 
several days. Moreover, it is important to consider that three-host ticks 
feed only once during each developmental stage (i.e. larva, nymph and 
adult). Therefore, it is important to consider the pre-moulting and 
moulting periods (from larva to nymph and from nymph to adult), while 
preparing infected ticks to be used in future challenges. 
Successful infection of the arthropods with the VBP of interest should 
be confirmed by dissection followed by microscopic examination or by 
molecular techniques (e.g., PCR) on a representative number of in-
dividuals. The minimal sample size to be tested should be calculated 
using expected infection rates in the vectors based on data obtained from 
previous field and/or laboratory studies. It is imperative to confirm that 
arthropods are infected by the pathogen of interest and also to assess the 
presence of other related pathogen species, which might be also present 
in the arthropods. If co-infections are confirmed, the arthropods may 
still be used, provided that diagnostic tools used to detect the infections 
in the experimentally challenged animals are able to distinguish be-
tween target and non-target VBPs. Highly specific serological tests, 
specific PCR protocols or generic PCR followed by DNA sequencing 
should be used for this purpose. For obvious reasons, arthropods 
ingesting an infected blood meal will immediately become DNA positive 
(due to carry-over of DNA), which, however, does not mean that the 
infection is successfully established in the arthropod vector. Thus, in the 
case of ticks, in which some VBPs may be passed transstadially or 
transovarially, testing should be done using subsequent developmental 
stages that will be used for the experimental transmission to ensure that 
the infection is actually established. When the same developmental 
stage of the arthropod will be used (e.g., female sand flies), testing 
should be done after a certain period of time to allow blood meal 
digestion and to ensure that the infection is established and the patho-
gen’s infective forms have developed (e.g., metacyclic promastigotes of 
Leishmania spp. take usually 5–7 days to develop). Once the infection 
rate has been established, whenever feasible, vector competence should 
be validated prior to use in a pivotal study, by challenging naïve animals 
with a batch of infected vectors. 
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The infection rates in the vectors vary widely according to pathogen 
and vector species. For instance, a study showed that 10–60 % of the 
nymphs of Amblyomma sculptum (reported as Amblyomma cajennense) 
were infected with R. rickettsii after feeding as larvae on infected guinea 
pigs, whereas 80–100 % of the nymphs of Am. aureolatum and Rh. san-
guineus s.l. were infected with the same pathogen (Labruna et al., 2008). 
Since vector challenge models aim at simulating natural exposures in a 
standardized and controlled manner in the laboratory, the infection 
rates in arthropods to be used in laboratory studies should generally 
reflect rates found in the field (Fourie et al., 2019). Therefore, it is not 
possible to define a precise minimal infection rate that would be 
required for laboratory studies. In theory, only one infected arthropod is 
necessary to infect a susceptible host. Thus, the most important thing is 
to demonstrate that most (if not all) untreated control animals become 
infected after experimental challenge, regardless of the infection rate 
detected in the infesting arthropods. Accordingly, the higher the infec-
tion rate that is detected in the infesting arthropods, the higher will be 
the chances to provide both treated and untreated animals with an 
actual “challenging’’ situation. Therefore, the infection rates found in 
the arthropods used in laboratory studies should always be reported in 
the study dossier submitted to the regulatory authority. 
4.2.2. Field studies 
As for laboratory studies, specific care should be taken to mitigate 
the risk of adverse events and any clinical signs related to the specific 
infection in exposed animals. Pet owners involved in the study should be 
aware of the study objective and design, any potential adverse events 
and of the limited liability of the sponsor and of the investigator. In 
addition, they should provide their written consent for the inclusion of 
their animals in the study and should be given the possibility to consult 
the investigator at any time. A rescue treatment, if any is available, must 
be clearly specified in the protocol in cases of infection detected in study 
animals. Field studies must be performed according to GCP guidelines if 
the results are intended to be submitted to a regulatory authority. 
Due to the risk of infection and disease development in privately- 
owned pets the use of an untreated group in field studies may not al-
ways be feasible. Whenever the inclusion of an untreated group is not 
possible, the inclusion of a treated control group (animals treated with 
an established treatment) is necessary. Under field conditions, the 
infection challenges are natural and baseline prevalence data should be 
generated prior to the study initiation. Knowing prevalence and, 
whenever possible, the incidence of the infection caused by the VBP 
under investigation, will allow the estimation of the sample size to be 
included in the study (see section ‘4.4. Sample size and methods for 
calculating the efficacy’). If treated and untreated groups are located in 
different areas (e.g., in pair matched-cluster randomized controlled 
studies) (Courtenay et al., 2019), baseline prevalence data are manda-
tory, also to guarantee that both groups are at similar levels of exposure 
to the risk of infection. The study design should consider several aspects 
that are inherent to the vector-pathogen system under study (e.g., vector 
seasonality pathogen transmission time and prepatent period) and 
intended product claim. 
4.3. General recommendations for diagnosing VBP infections in dogs and 
cats 
Various diagnostic methods are available to infer or to confirm VBP 
infection in dogs and cats. Each pathogen may be more reliably detected 
by a test or a group of tests at different times considering specific factors 
such as their prepatent periods and any possible effects of seasonality in 
the infection dynamics (e.g., seasonal and circadian variation of 
microfilaraemia of Dirofilaria spp.) (Ionică et al., 2017). For antibody 
testing, the time needed for seroconversion must be considered when 
defining the earliest meaningful testing time point. In both laboratory 
and field studies, animals should be tested before the inclusion, in order 
to assess their negativity at the beginning of the study and at following 
time-points. Hence, according to the peculiarities of specific pathogens 
and diagnostic tests used, the frequency of testing varies largely (for 
specific recommendations see Section 5). For tick-borne pathogens, a 
combination of tests aiming at different targets (e.g., pathogen DNA 
detection by PCR and pathogen antibody detection by serological test) 
should be used. The direct visualization of some pathogens (e.g., Ana-
plasma spp., Babesia spp. and Ehrlichia spp.) in peripheral blood smears 
may be extremely challenging due to the low parasitaemia, which is a 
frequent occurrence in chronically infected dogs. However, the level of 
parasitaemia is also dependent on individual host factors and whenever 
possible, cytological examinations of buffy coat, bone marrow and 
lymph node smears should be performed, particularly in field studies 
when mixed vector-borne infections may occur. When co-infections 
occur, a diagnosis based on clinical signs is challenging considering, 
for example, the similar alterations occurring in animals co-infected by 
tick-borne pathogens or L. infantum. In that case, different PCR pro-
tocols, various target genes and distinct clinical samples (e.g., bone 
marrow, lymph nodes, skin, buffy coat and blood) have been shown to 
be useful for the diagnosis of multiple VBPs, with different degrees of 
sensitivity and specificity among protocols (Otranto et al., 2009) and 
should be used according to the most recent literature. In addition, 
molecular tools have advanced the diagnosis of many VBPs overcoming 
difficulties in culturing some pathogens (e.g., Bartonella spp.), 
enhancing the sensitivity and specificity, accelerating the time between 
sample collection and test result, and allowing a rapid expedition of the 
appropriate chemotherapy. Where necropsy results are used for worm 
counts in laboratory studies (e.g., in experimental infections with 
D. caninum or Di. immitis) the correct timing post-infection must be 
observed (usually around 5–6 months for Di. immitis and 1–3 months for 
D. caninum). For recommendations on specific pathogens, see Section 5. 
4.4. Sample size and methods for calculating the efficacy 
Laboratory studies typically require a smaller sample size in com-
parison with field studies, in which the level of exposure to vectors and 
pathogens may vary widely. The number of animals in each group 
should be sufficient to demonstrate successful infection in the control 
animals and obtain a significant difference (typically p < 0.05) when 
compared to the treated group. In most laboratory studies, a minimum 
of 6–10 animals per group is sufficient. The number of animals included 
in field studies is usually higher than in laboratory studies. The calcu-
lation of the appropriate sample size for detecting a difference between 
two proportions requires data on the expected proportion in the treated 
and untreated groups (defined either theoretically or based on existing 
prevalence/incidence data), confidence level (typically 95 %) and 
desired power (usually 80 %). The sample size calculation method 
should be clearly reported in the study dossier. The number of animals 
per group should also account for potential losses (e.g., owner unwill-
ingness to continue in the study, non-allowed concomitant treatments, 
death and collar loss in case of studies with collars). Though it is com-
mon to include 50–100 animals per group, a smaller number of animals 
might be accepted according to the minimum sample size calculation. 
Non-inferiority studies also require defining the non-inferiority limit 
(Wang and Chow, 2007). In this case, it should be usually assumed that 
the percentage of protection in both standard and experimental treat-
ment groups is the same. 
Different methods can be used to calculate the efficacy of parasiti-
cides in preventing VBP transmission in laboratory and field studies. 
These methods may vary according to study design and the VBP of in-
terest. In long-term studies, the efficacy calculation can consider the 
number of infected animals at a given time point, with animals not 
completing the study being not usually considered in the efficacy 
calculation. Nonetheless, results from animals removed during the 
course of the study, according to pre-defined post-inclusion removal 
criteria, can still be included in the statistical assessment (e.g., using the 
‘last observation carried forward’ approach). Alternatively, the 
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incidence density rate (IDR) (also known as ‘animal-time incidence 
rate’) can be used, allowing the inclusion of data from animals that did 
not complete the study in the efficacy calculation (Otranto et al., 2010a). 
In either case, animals tested only once in long-term studies do not 
contribute to the efficacy calculation. 
In laboratory studies, in which VBPs can be counted at necropsy (e. 
g., D. caninum and Di. immitis) at the end of the observation period, 







x100 (1)  
where Mc and Mt are the arithmetic mean of parasites found at necropsy 
in animals in the control and treated groups, respectively. 
When VBPs cannot be precisely counted (e.g., in laboratory studies 
dealing with bacteria and protozoa) or when necropsy is not an option 
(e.g., in field studies), the preventive efficacy is usually calculated using 






x100 (2)  
where Tc and Tt are either the number of infected animals or the IDR in 
control and treated groups, respectively. 
An alternative approach proposed to calculate the percentage of 
protection of parasiticides against VBP transmission is based on number 
of challenges until an animal is successfully infected in a laboratory 
study (Jongejan et al., 2015). According to the authors, this approach 







x100 (3)  
where IcC is the number of infective tick challenges conducted in the 
control group that lead to positive infection and IcT, the number of 
infective tick challenges in the treated dogs that lead to infection. 
In non-controlled studies, the efficacy cannot be calculated using the 
above-mentioned formulae. In this case, the authors should report the 
percentage of protection conferred by the product to treated animals 
providing supportive evidence to show that the product protected the 
animals from VBP transmission. For instance, an uncontrolled field 
study on heartworm prevention conducted in Brazil provided evidence 
by reporting prevalence data obtained from untreated animals living in 
the study area, at baseline and at the end of the study (Labarthe et al., 
2015). Nonetheless, it is important to emphasize that this is supportive 
evidence and does not confirm the efficacy of the investigational prod-
ucts. Therefore, protection data from uncontrolled field studies cannot 
be used for registration purposes. 
Differences in the calculated prevention efficacy between control 
and treatment groups should be shown to be statistically significant 
(typically p < 0.05) using a suitable statistical test. For non-inferiority 
studies, the protection in the experimental group should not be signifi-
cantly less efficacious than the treatment standard. 
5. Specific study designs 
5.1. Prevention of flea-borne pathogen transmission 
The efficacy of a parasiticide against fleas can be evaluated as early 
as 15 min post-infestation by collecting all on-host live, moribund and 
dead fleas from treated and untreated animals (Marchiondo et al., 
2013). In the case of parasiticides acting topically through contact as 
well as parasiticides acting systemically, which require fleas to ingest 
the active compound(s) with the host’s blood, the effects on the feeding 
depend on the nature, mechanism of action and SOK of the active 
ingredient(s). To quantify flea feeding, a real-time PCR assay can also be 
used to determine the amount of host DNA in the fleas collected from 
treated and untreated animals, allowing for appropriate comparative 
statistical analysis (Wang et al., 2012). Simple haemoglobin strips or 
simply viewing fleas under a light microscope can also provide quali-
tative information on flea blood feeding. The vast majority of fleas 
usually feed within 1 h of infestation and each flea usually takes several 
blood meals on the same host (Cadiergues et al., 2000). This implies the 
need for very rapid control of flea infestations to reduce the risk of 
pathogen transmission, especially in the light of limited available 
knowledge on transmission times of Rickettsia felis and Bartonella hen-
selae (Eisen and Gage, 2012). Therefore, independent of the VBP species, 
the best approach to prevent flea-borne infections is minimizing the 
establishment of flea infestations on dogs and cats. Accordingly, the 
approach for preventing flea-borne pathogen transmission should aim at 
killing the majority (>95 %) of fleas as quickly as possible, ideally 
within 1 h of infestation. However, considering that fleas usually start 
laying eggs within 24 h from the initiation of their blood feeding (Akin, 
1984), the 24 h time point has been considered as critical to demonstrate 
satisfactory efficacy (>95 % in Europe and >90 % in the USA) of 
parasiticide products against fleas in Europe (Marchiondo et al., 2013; 
EMA, 2016a). So far, no laboratory or field studies have been conducted 
for assessing the efficacy of parasiticides in preventing flea-borne 
transmission of R. felis in cats, but the design of such studies should 
generally follow the design adopted for Ba. henselae studies, as described 
in the following section. 
5.1.1. Prevention of Bartonella henselae transmission 
Bartonella henselae is a widespread vector-borne bacterium, usually 
associated with cats. It is the aetiological agent of ‘cat scratch’ disease in 
humans. Laboratory studies to assess the prevention of Ba. henselae 
transmission to cats have used fleas infected either via feeding on 
experimentally infected cats (Bradbury and Lappin, 2010; Lappin et al., 
2013) or via artificial feeding systems (Bouhsira et al., 2015). The use of 
artificial feeding systems to infect fleas is more ethically acceptable and 
provides a more homogeneous source of infected fleas. Laboratory 
studies using fleas infected on cats need three groups (at least six cats per 
group): a group of experimentally infected Ba. henselae positive cats as 
source of infection, flanked by a group treated with the investigational 
product and an untreated group in a way that allows spreading of the 
flea infestation. The Ba. henselae positive cats are experimentally infes-
ted with fleas and the cats in all groups are followed up weekly or 
biweekly for the duration of the study (Bradbury and Lappin, 2010; 
Lappin et al., 2013). In laboratory studies using fleas infected via arti-
ficial feeding the two groups of animals needed are directly infested with 
the thus infected fleas (Bouhsira et al., 2015). 
Field studies should include treated and untreated cats, with a higher 
number of cats per group (for sample size calculation, see Section 4.4) 
and a longer follow up (at least 1 year) than laboratory studies. The 
preventive efficacy in both laboratory and field studies is calculated 
using the formula (2) based on number of infected animals as described 
in Section 4.4. 
For laboratory studies with Ba. henselae in cats, serology, blood 
culture and PCR are recommended, with testing being performed weekly 
or biweekly for 42–252 days, depending on the efficacy period of the 
investigational product (Bradbury and Lappin, 2010; Lappin et al., 2013; 
Bouhsira et al., 2015). Cats included in field studies targeting Ba. hen-
selae should be tested monthly or every 2–3 months, for at least 1 year. 
5.1.2. Prevention of Dipylidium caninum transmission 
The control of D. caninum infection must primarily rely on regular 
deworming of dogs and cats with a product containing a cestocidal 
molecule (e.g., praziquantel) (CAPC, 2018; ESCCAP, 2017). The added 
preventive effect of parasiticides against the intermediate hosts of this 
tapeworm (primarily fleas but also lice) aids in the control as frequency 
of deworming may be insufficient. The parasiticide should rapidly kill 
D. Otranto et al.                                                                                                                                                                                                                                 
Veterinary Parasitology 290 (2021) 109369
9
>95 % fleas to stop the development of the D. caninum cysticercoid into 
the infective stage (Pugh and Moorehouse, 1985), thus preventing 
D. caninum transmission, even if killed fleas are eventually ingested. 
To obtain adult fleas to infest dogs and cats, flea larvae should be 
exposed in vitro to proglottids and eggs of D. caninum (Fourie et al., 2012, 
2013e). Prior to each host infestation, the prevalence and mean intensity 
of infection with cysticercoids and degree of development of cysticer-
coid need to be determined by microscopic dissection of batches of the 
adult fleas (~100) (Fourie et al., 2012, 2013e; Gopinath et al., 2018). 
Dogs and cats have to be infested with unfed infected fleas of mixed 
sex, with flea numbers ranging from 100 to 250 specimens, depending 
on the infection intensity determined; higher numbers of fleas should be 
used if infection intensity is relatively low. Infestations start on day 
0 and continue usually weekly after treatment (e.g., on day 7 onwards), 
depending on the aspired duration of efficacy. 
The efficacy evaluation is normally based either on necropsy counts 
of scolexes in the small intestine or macroscopic examination of faeces 
for shed proglottids. For necropsy counts, dogs and cats have to be 
euthanized at the end of the prepatent period (i.e. at least 4 weeks after 
the last flea infestation in cats and dogs) although necropsy examination 
for scolex detection should not be too delayed compared to the prepatent 
period, as self-cure may also occur (Craig et al., 1991). Scolexes of 
D. caninum are then counted allowing the efficacy calculation using the 
mean of adult worms in treated and untreated animals (see Section 4.4.). 
An alternative approach could be the daily examination of study animals 
(Beugnet et al., 2013; Gopinath et al., 2018) from the end of the pre-
patent period, to detect proglottids in freshly shed faeces or around the 
anal and perianal regions, in their fur or in their cages as described 
elsewhere (Fourie et al., 2012, 2013e; Beugnet et al., 2013). The reli-
ability of recovering proglottids in the faeces is however affected by the 
inconsistent shedding of D. caninum proglottids in patent animals, which 
is not directly related to the degree of infection. A critical test, such as 
treatment with praziquantel and recovery of worms from faeces could be 
a valid alternative for evaluating the efficacy of the product. The pre-
ventive efficacy is then calculated using either the formula based on 
parasite counts (1) (i.e. when necropsy is feasible) or on infested animals 
(2) (i.e. when necropsy is unfeasible), as described in Section 4.4. 
5.2. Prevention of tick-borne pathogen transmission 
Tick repellency can be assessed in vitro and in vivo as described 
elsewhere (Marchiondo et al., 2013). Products that repel or rapidly kill 
ticks have the potential to reduce the risk of tick-borne pathogen 
transmission, with the transmission time of the specific pathogen tested 
largely determining the SOK needed to successfully prevent trans-
mission. Nonetheless, transmission efficiency by ticks as well as the 
establishment of infections in dogs increases with time (i.e. the longer 
the feeding period, the higher is the probability of successful trans-
mission), for some pathogens being apparently dependent on a mini-
mum inoculation dose. The efficacy of an investigational product in 
preventing tick-borne pathogen transmission can be assessed under 
laboratory conditions by infesting treated and untreated animals (usu-
ally from 6 to 10 per group) with ticks infected by a given pathogen. The 
number and developmental stages of ticks may vary widely according to 
tick species, developmental stage, pathogen species and infection rate in 
ticks. Ticks can be applied directly on the animals or placed next to the 
animals in infestation crates or cages to mimic natural challenges. 
Ideally ticks should be left on the animals until completely engorged. 
Following the first tick challenge, animals should be monitored daily 
for the appearance of clinical signs potentially related to the infecting 
pathogen. Rectal body temperature, mucous membrane colouration, 
capillary refill time and haematocrit are amongst the most common 
parameters to be checked. Tick-borne pathogens should be detected by 
cytology, blood culture, serology or PCR. In most cases, cytology and 
culture are not sensitive enough and PCR on blood samples is the 
preferred technique. Serology can be used whenever available, but 
cross-reactions between closely related pathogens are frequent and 
should be accounted for. In laboratory studies, testing of animals is 
usually performed before experimental challenge and then weekly or 
biweekly for around 2–3 months or longer, according to specific path-
ogens (Fourie et al., 2013d; Honsberger et al., 2016; Taenzler et al., 
2016; Geurden et al., 2017). In field studies, considering the seasonality 
of tick infestation (Lorusso et al., 2010), the variable prepatent periods, 
the transient parasitaemia/bacteraemia and the uncertainty regarding 
the exact day (or days) of exposure to infected ticks, dogs and cats 
should be tested every 2–3 months, for at least 1 year (Otranto et al., 
2010b; Dantas-Torres et al., 2013). While the number and timing of 
follow ups may be adapted to the needs of each study, animals should be 
tested at least before inclusion, at the end efficacy period of the inves-
tigational product and at the end of an observational period. The pre-
ventive efficacy in both laboratory and field studies targeting tick-borne 
pathogens is calculated using a formula based on number of infected 
animals (2) or number of challenges up to successful infection (3) as 
described in Section 4.4. 
5.2.1. Anaplasma spp. Ehrlichia spp. and Rickettsia spp. 
In laboratory studies, competent tick vectors should be used to 
transmit Anaplasma spp., Ehrlichia spp. and Rickettsia spp. to dogs and 
cats. The vector of A. platys is still unknown, and no laboratory studies 
have successfully achieved transmission of this bacterium by ticks, but 
field studies have suggested that tick repellents are efficacious in 
reducing the risk of A. platys transmission to dogs (Dantas-Torres et al., 
2013). Transmission times are variable but might occur in less than 3 h 
(E. canis) to 10 h (R. rickettsii). Therefore, the preventive efficacy should 
be assessed at different time points, depending on the intended claim, 
being at least 3 h for E. canis, 10 h for R. rickettsii and 48 h for 
A. phagocytophilum, for instance. 
Rickettsial pathogens infecting dogs and/or cats are found in 
mononuclear leukocytes (E. canis, Ehrlichia chaffeensis), granulocytes 
(A. phagocytophilum, Ehrlichia ewingii), platelets (A. platys), or endothe-
lial cells of small blood vessels (R. rickettsii), appearing in circulating 
blood within a few weeks after transmission by ticks. As such, diagnosis 
may be confirmed by cytology of blood smears, which is usually rec-
ommended only in the acute phase due to the short-lasting bacteraemia; 
inclusion may be difficult to find even in the acute phase. Analogously, 
PCR on blood samples may result in false negative results in the chronic 
phase whereas it is highly sensitive in the acute phase, even considering 
that these organisms are not consistently present or detected in circu-
lation. Serological tests, including indirect fluorescent antibody (IFA) 
and enzyme-linked immunosorbent assays (ELISA), are available to 
confirm exposure to those agents, although cross-reactions are common 
and should be considered. Because dogs are often seronegative during 
the initial clinical disease, serology should be repeated every 2–3 weeks. 
In addition, a four-fold increase in IgG titre or a single IgG titre >1024 
on IFA are usually considered diagnostic. Culture of these organisms are 
not usually attempted. 
5.2.2. Borrelia spp. 
Borrelia burgdorferi is passed transstadially from a developmental tick 
stage to another. Nymphs and adults, experimentally infected as larvae 
and nymphs, respectively, may be used as a source of infection. Trans-
mission of Borrelia spp. spirochetes by infected ixodid ticks occurs from 
24 to 48 h following attachment to the host (Hajdušek et al., 2013) and 
therefore, the prevention efficacy should be assessed from 24 h. The 
diagnosis may be confirmed by serological tests, including 
whole-cell-based IFA or ELISA, which are commercially available for the 
diagnosis of Bo. burgdorferi. Since Bo. burgdorferi spirochetes enter the 
connective tissue upon tick inoculation, cytology of synovial fluid using 
dark-field microscopy is more effective than cytology of circulating 
blood and blood smear. Other diagnostic methods include culture 
isolation (though rather challenging and requiring relatively low density 
of organisms present in chronic infections), and molecular detection of 
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Bo. burgdorferi DNA in affected tissues. 
5.2.3. Babesia spp. 
Infective unfed or partially infected ticks (males and females but also 
nymphs) should be used for the experimental infection. For most of the 
Babesia spp. the transmission times are unknown but, considering data 
available for B. canis (transmitted about 36 h but only 8 h in interrupted 
feeding experiments) (Varloud et al., 2018), the preventive efficacy 
should be assessed from 24 h. The diagnosis may be performed by blood 
smear cytology from approximately 1–3 weeks, by molecular tests (both 
conventional and quantitative PCR are available) from 7 to 10 days and 
or by serology after 3–4 weeks. Blood samples should be collected for 
serum analysis at two, three, up to four or more weeks following 
exposure to infected ticks. Serology (IFA and ELISA assays are available) 
may not be useful in detecting acute infections and cross-reactions be-
tween different Babesia spp. may occur and should be considered in field 
studies, in areas where more than one Babesia spp. may circulate among 
dog and cat populations. 
5.2.4. Cytauxzoon spp. and Hepatozoon spp. 
In laboratory studies with Cytauxzoon spp. (typically Cytauxzoon 
felis), the transmission should be done by exposing cats to the bites of 
infected ticks (nymphs, males and/or females). Since transmission oc-
curs within 48 h, the preventive efficacy should be assessed within 48 h 
after treatment or infestation. Diagnosis should be confirmed by iden-
tification of Cytauxzoon spp. inclusions in blood smears and/or fine 
needle aspirates from the liver, spleen and lymph nodes and the obser-
vation of schizont-infected myeloid cells confirms acute disease. Since 
the sensitivity of blood smears may be low, fine needle aspirates and 
cytology of liver, spleen, lymph nodes and lungs are indicated if blood 
smears are not diagnostic in a suspected case. Importantly, Cytauxzoon 
spp. inclusions in erythrocytes cannot be reliably distinguished from 
Babesia spp. inclusions in cats. Hence, PCR assays, which are more 
sensitive and specific than the cytological observation, should be 
employed to confirm the infection in both laboratory and field studies. 
In laboratory studies with Hepatozoon spp., the transmission is per-
formed by feeding dogs with infected nymphs, males and/or females. 
Considering that the transmission of Hepatozoon spp. is immediately 
following ingestion of ticks, reducing the tick infestation levels in the 
environmental is probably the only effective way to reduce the risk of 
infection in dogs (Dantas-Torres et al., 2013). The diagnosis of H. canis is 
achieved via blood smear cytology by detecting typical gamonts in 
mononuclear cells from 28 days post-infection, whereas that of 
H. americanum is also based on the finding of meronts in muscle biopsy 
samples (Baneth, 2011). Molecular tests (both conventional and quan-
titative PCR are available) on blood samples are the most sensitive 
methods for diagnosing H. canis even in low parasitaemic individuals. 
5.3. Prevention of pathogen transmission by flying insects 
A high repellent efficacy (typically inferred from the anti-feeding 
effect) of a parasiticide is the main desired feature for the prevention 
of the disease transmission of VBPs by flying insects. While a high killing 
efficacy cannot protect an individual animal from becoming infected, it 
may contribute to control the infection rate in the vector population, 
thus interrupting the propagation of a VBP, as demonstrated for Di. 
immitis (McCall et al., 2017b). Previous W.A.A.V.P. guidelines (March-
iondo et al., 2013) did not consider flying insects and the assessment of 
the repellent and killing efficacy for this group of arthropod vectors is 
briefly described below. 
5.3.1. Assessing the repellent and killing efficacy against flying insects 
Without specific guidelines such as those available for fleas and ticks 
(Marchiondo et al., 2013), laboratory studies conducted from 1997 to 
2018 to assess the repellent and killing efficacies of topical formulations 
against sand flies (reviewed by Fondati et al., 2018) have progressively 
tended to reach a consensual, not yet definitive, protocol. Groups typi-
cally consist of 6–8 animals. The number of female sand flies (4–8 days 
old or older) used for each challenge ranges from 75 to 200, and a few 
males are included in the cages to promote biting. Exposure of dogs to 
sand flies typically lasts for 1–2 h (Fankhauser et al., 2015). Dogs may 
eventually be tested for natural attractiveness to sand flies, because of 
the wide individual variation detected in these animals (Bongiorno 
et al., 2013). In this case, allocation to treated and untreated groups is 
made by ranking dogs according to their individual pre-treatment sand 
fly engorgement test results (Bongiorno et al., 2013; Bouhsira et al., 
2018), and the least attractive dogs are discarded. A properly sized cage 
should prevent accidental contacts between sand flies and treated dogs, 
which may occur in smaller cages. Ideally, a cage should be at least 100 
cm in length, 75 cm in width and 90 cm in height if medium-size Beagle 
dogs are used. After exposure time, female sand flies should be carefully 
collected using mouth aspirators, avoiding unwanted damage of these 
delicate insects. This must be done by careful observation of the expo-
sure cage for any visible flies, prior to and after removal of the dog. 
Additionally, compressed air can be blown into the dog’s hair to help 
recover any remaining insects lodged in the fur. Infestations should start 
when the efficacy is supposed to start (day 1 or 2 or even later) after 
treatment (day 0) and continue after treatment (e.g., weekly or biweekly 
from day 7 onwards), depending on the aspired duration of efficacy. 
Repellent efficacy against flying insects (e.g., mosquitoes and sand 
flies) is usually inferred from the anti-feeding effect produced by the 
investigational product. In practice, the repellent efficacy can be eval-
uated by exposing treated animals to the insects for 1–2 h, after which 
insects are counted and categorized as ‘fed’ or ‘unfed’. Female sand flies 
or mosquitoes with red enlarged abdomens are considered as ‘fed’ (or 
‘engorged’), while those with no evidence of blood in their abdomen are 
considered as ‘unfed’. Then, the repellent/anti-feeding efficacy (%) 







where Cf and Tf are the arithmetic mean of fed females in control and 
treated groups, respectively. 
The repellent efficacy calculated using arithmetic means from un-
treated and treated groups (EMA, 1994) may not be sufficient for the 
appraisal of persisting and homogeneous repellent effect on sand flies 
over time, as a result of the highly variable feeding data from control 
dogs. The recommended EMA formula can eventually be complemented 
by longitudinal sets of fed-to-unfed female ratios as described elsewhere 
(Bouhsira et al., 2018). 
The insecticidal efficacy of flying insects should not only be assessed 
shortly after exposure to treated animals, but for up to 24–72 h following 
exposure (WHO, 2005), when insects are counted and categorized as 
‘live’, ‘moribund’ or ‘dead’. Insects are considered as ‘live’ when they 
exhibit normal behaviour and are capable of flying, ‘moribund’ when 
they are unable to move normally and are incapable of coordinated 
locomotion or flight upon external stimuli, and ‘dead’ when they are 
incapable of any behaviour and lacking any movement upon external 
stimuli. The killing efficacy (%) can be then calculated at different time 
points (e.g., 1, 2, 4 or even 20 h after exposure) (Killick-Kendrick et al., 







where Cl and Tl are the arithmetic mean of live females in control and 
treated groups, respectively. 
5.3.2. Prevention of Dirofilaria spp. transmission 
Though most of data about the prevention of Dirofilaria spp. refer to 
Di. immitis, they should be considered equally valid for Dirofilaria repens, 
which has a very similar biology in relation to the extrinsic incubation 
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period in the vector and prepatent period in the definitive host. Over the 
past 3 decades, dirofilariosis, especially heartworm disease prevention 
in both dogs and cats has essentially been based on the chemoprophy-
lactic use of MLs (i.e. ivermectin, milbemycin oxime, moxidectin and 
selamectin) targeting the third- and fourth-stage migrating larvae (L3s 
and L4s) of Di. immitis (Bowman and Atkins, 2009). 
However, repelling mosquitoes constitutes an important component 
in the control of Di. immitis, as proven in a laboratory study showing that 
repelling and killing mosquitoes prevented the transmission of this 
parasite to dogs (McCall et al., 2017a). The use of this ‘double defence’ 
strategy using a permethrin-containing product together with an ML was 
more efficacious than the monotherapy (with the same ML) in protecting 
dogs from becoming infected with a Di. immitis isolate with reduced 
susceptibility to the same ML (McCall et al., 2017a). This integrated 
prevention strategy is now also included in the Guidelines of the 
American Heartworm Society (AHS, 2018). However, environmental 
stressors not normally applied under laboratory conditions, like sunlight 
and bathing, may reduce the overall duration of efficacy of repellent 
products (Blagburn et al., 2015), potentially limiting the added repel-
lency benefit of integrated strategies (American Heartworm Society, 
2018). This, once again, emphasizes the need for field studies. 
In order to demonstrate the efficacy of a parasiticide in preventing 
transmission of Di. immitis L3s, a study should employ infected female 
mosquitoes and assess the presence/absence of adult worms in exposed 
animals 5–6 months after the challenge (McCall et al., 2017a). Female 
mosquitoes can be infected in vitro by feeding on blood with micro-
filariae (McCall et al., 2017a). The estimated number of L3 transmitted 
to each dog should be calculated before each exposure by dissecting 
individual mosquitoes (at least three mosquitoes from each batch). Dogs 
or cats should be exposed to not less than 50 mosquitoes for 1 h, under 
sedation, within individual mosquito-proof containers. Using infected 
mosquitoes not older than 21 days is therefore advisable as, as in older 
mosquitoes the feeding behaviour is impaired and can therefore appear 
as disrupted (Gleave et al., 2016). 
Calculating the efficacy of a product in preventing the transmission 
of Di. immitis requires dogs or cats to be humanely euthanized and 
necropsied from 5 to 6 months after the mosquito challenge (i.e. after 
worms reach pulmonary arteries but before they reach maximum size 
and increase risk of clinical signs). At necropsy, all (presumably adult) 
worms should be collected from the heart and associated pulmonary 
arteries, but also the pleural and peritoneal cavities, and enumerated. 
The preventive efficacy in laboratory studies involving experimental 
infection and necropsy is calculated using the formula (1) described in 
Section 4.4. 
Field studies conducted so far assessing the efficacy in killing L3s and 
L4s of Di. immitis by means of MLs in dogs have adopted distinct designs 
(Boy et al., 2000; Genchi et al., 2002; Moraes-da-Silva et al., 2016). 
Animals positive to adult antigens 120 days post-infection should be 
removed from the study, as previous exposure cannot be ruled out 
(Carmichael et al., 2017). Treated and untreated groups should include a 
representative number of animals, which depends on the force of 
infection in the study area (see Section 4.4 for sample size calculation). 
Animals should be followed up for at least 1 year and testing should be 
performed at least before inclusion, on days 120, 180 and 360. When-
ever feasible, animals can be followed up monthly or every 2–3 months 
from day 120 until the end of the observational period. For Di. immitis, 
the modified Knott test and serological tests targeting antigens of adult 
female worms can be used (Knott, 1939). However, these only show 
reliable results from 180 to 190 days after infection, when Di. immitis 
adults are formed and females are producing the first microfilariae. The 
preventive efficacy in field studies should be calculated using the for-
mula (2) as described in Section 4.4. 
5.3.3. Prevention of Leishmania spp. transmission 
The assessment of the L. infantum prevention efficacy under labora-
tory conditions is not an easy task. Tests employing sand flies 
experimentally infected with L. infantum are usually impracticable, as 
under laboratory conditions only a small proportion of these vectors will 
survive after the first infectious blood meal, and an even smaller pro-
portion will be willing to feed again (Aslan et al., 2016). Therefore, the 
only parameters that can be reliably calculated in laboratory studies are 
repellent and killing efficacies against sand flies (Bouhsira et al., 2018). 
In the absence of a feasible laboratory model, field studies are pivotal 
to assess the efficacy of an investigational product in preventing 
L. infantum transmission in dogs and cats (Otranto and Dantas-Torres, 
2013). Several field studies using topical formulations containing py-
rethroids were performed from 2001 to 2016 (reviewed by Fondati 
et al., 2018). Studies should be conducted in areas where competent 
sand fly vectors are known to occur. Stringent inclusion criteria should 
be used to diminish the probability of including already infected dogs. 
The use of naïve purpose-bred dogs may overcome this problem 
(Papadopoulos et al., 2020), but this is not always feasible. In areas 
where L. infantum transmission is seasonal (e.g., in the Mediterranean 
region), this problem may also be overcome by including young dogs 
that were born during the winter season. Data on the prevalence and/or 
incidence of canine Leishmania infection in the study area is necessary 
for sample size calculation purposes (see Section 4.4). If the study is 
performed within a large territory (e.g., hilly to coastal level or rural to 
urban areas), control and treated dogs should be equally distributed over 
the different environmental conditions within the territory, to ensure 
that study animals are challenged with an equivalent level of L. infantum 
transmission risk. Randomization and allocation of animals to treated 
and control groups should be done by household, as treated and control 
animals should not be co-housed. 
For L. infantum, dogs may become positive (e.g., cytology, culture, 
PCR and/or serology) 1–2 months after being bitten by infected sand 
flies, but the prepatent period and the time required for seroconversion 
may vary widely. Therefore, dogs and cats involved in field studies 
targeting L. infantum should be followed up for at least 1 year. The 
frequency of testing may be flexible, but animals should be assessed at 
least before inclusion, at the end efficacy period of the investigational 
product and at the end of an observational period. However, whenever 
feasible, it is advisable to test animals every 3–4 months in order to 
detect early positivity in exposed animals, though it may be more 
difficult in some field studies, particularly with cats (Brianti et al., 
2017). The preventive efficacy in both laboratory and field studies is 
calculated using the formula (2) as described in Section 4.4. For field 
studies using a positive control group, a non-inferiority approach should 
be used. Considering the low sensitivity of cytology and culture, the 
combined use of serology and PCR is recommended. Serology should 
preferentially be performed using quantitative methods and PCR using 
reliable tissue samples (e.g., bone marrow, lymph nodes or conjunctival 
swabs). Blood may be the only convenient sample type to be used in 
large-scale field studies, but in this case the use of a highly sensitive 
real-time PCR assay validated for this type of sample is recommended. 
Cross-reactions with other Leishmania spp. (e.g., Leishmania braziliensis 
in Latin America) and other trypanosomatids are common and should be 
considered when interpreting serological results. In the same way, most 
PCR assays designed for targeting L. infantum will also amplify DNA 
from other Leishmania spp. (Dantas-Torres et al., 2017). Therefore, 
serological and PCR results should be interpreted with cautious in field 
studies, where different trypanosomatids may coexist. 
6. Conclusions 
The increasing importance and expanding distribution of VBDs in 
companion animals highlight the need for safe parasiticides with proven 
efficacy against VBP transmission. Efficacy against arthropods might not 
per se imply a reduction of the risk of VBP transmission by these ar-
thropods. In fact, the current requirements for such claims (e.g., treat-
ment and control of flea and tick infestations) (Marchiondo et al., 2013) 
do not allow any a priori conclusion in this sense. Therefore, even 
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products with proven efficacy against arthropod vectors need to be 
tested for their specific potential to reduce the risk of VBP transmission 
to achieve respective label claims. The present guidelines provide rec-
ommendations for studies evaluating the efficacy of parasiticides in 
reducing VBP transmission in dogs and cats. Considering the variability 
in VBP transmission patterns, strict efficacy threshold requirements in 
either laboratory or field studies cannot be requested by regulatory 
authorities. Nonetheless, products should display statistically significant 
efficacy in the overall prevention of VBP transmission in treated animals 
compared to untreated controls, or non-inferiority to an already 
approved product when the inclusion of an untreated control group is 
unfeasible. 
There are still significant gaps in our understanding of many aspects 
of VBP transmission, such as transmission times of several VBPs (e.g., 
A. platys, B. gibsoni, Ba. henselae, Rangelia vitalii and R. felis) or even the 
vector identity of some agents (e.g., A. platys and Onchocerca lupi). We 
therefore advocate for future studies to increase such knowledge and to 
allow a continuous advancement as well as widening of these recom-
mendations to include further relevant pathogens. 
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dently reviewed by 6 peer reviewers who offered independent and 
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Glossary 
Vector: an organism (especially an arthropod) that carries and transmits a pathogen from 
one host to another 
Anti-feeding effect: the action of a product that causes ectoparasites to fail to feed on the 
host 
Control of ticks and fleas: the act of reducing the population of arthropods (both on animals 
and environment) or pathogen transmission by means of different approaches (e.g., 
the use of chemical insecticides and acaricides, vaccination or biological control) 
Curative efficacy: the efficacy of an ectoparasiticide product to solve a pre-existing, already 
established infestation. Applicable to ‘permanent’ ectoparasites such as adult fleas, 
ticks, mites and lice 
Efficacy: the extent to which a product achieves its intended effect under ideal circum-
stances (e.g., controlled clinical studies) 
Incidence density rate: the number of new cases of disease during a defined period of time, 
divided by the sum of individual-time of the population at risk 
Interrupted feeding: when an arthropod feeding process on a vertebrate host is interrupted 
after the initiation of the blood meal 
Killing effect: the action of a product that causes the death of ectoparasites 
Non-inferiority studies: studies designed to demonstrate that the test product is not inferior 
to the comparator (i.e. a product with proven efficacy). These studies require defining 
the non-inferiority limits 
Persistent (residual) efficacy: extended activity of a product measured in days or weeks after 
initial treatment 
Pre-activation: The time a pathogen requires in the vector to complete its development into 
a transmissible state 
Prepatent period: the time between infection of the host and the earliest time at which 
parasitic immature forms (usually infective to the arthropod vectors) occur 
Prevention: the act of preventing something, including ectoparasitic infestation and path-
ogen transmission 
Repellent effect: the action of a product that causes ectoparasites to avoid or leave the host 
Speed of kill: the time required for a product to kill a stated, non-negligible percentage 
(usually between 90 and 95 %) of ectoparasites 
Transmission time: the time required from initiation of feeding by the arthropod vector to 
actual pathogen transmission to the host 
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